FTH insider buying and SEC filings, explained
Faeth Therapeutics, Inc. · CIK 1829802
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Sensei Biotherapeutics, Inc.
Insider activity in the last 12 months
Bought
$2.5M
Insiders who bought
3
Sold (not marked 10b5-1)
$2.3M
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 29–Jul 1, 2026 | Purchase (code P) | Brian C. Stephenson (CFO) bought 13,634 shares indirectly between Jun 29 and Jul 1 at about $23.92 ($326K), reported as a purchase (code P). Indirect holdings up 41% to 46,688 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 1, 2026 |
| Jun 24–26, 2026 | Purchase (code P) | Brian C. Stephenson (CFO) bought 15,641 shares indirectly between Jun 24 and Jun 26 at about $25.65 ($401K), reported as a purchase (code P). Indirect holdings up 90% to 33,054 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 26, 2026 |
| Jun 22, 2026 | Purchase (code P) | Anand Kiran Parikh (CEO and Director) bought 2,806 shares at $19.76 ($55K), reported as a purchase (code P). Holdings up <1% to 764,234 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 24, 2026 |
| Jun 22–23, 2026 | Purchase (code P) | Brian C. Stephenson (CFO) bought 17,413 shares indirectly between Jun 22 and Jun 23 at about $23.31 ($406K), reported as a purchase (code P). New position of 17,413 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 24, 2026 |
| Jun 1, 2026 | Sale | Cambrian BioPharma Inc (10% owner) sold 25,000 shares at about $20.02 ($501K). Holdings down 16% to 130,142 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 1, 2026 |
| Jun 1, 2026 | Sale | James Peyer (Officer and 10% owner) sold 25,000 shares at about $20.02 ($501K). Holdings down 16% to 130,142 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 1, 2026 |
| Apr 2–7, 2026 | Sale | Israel A. Englander (10% owner) sold 17,076 shares indirectly between Apr 2 and Apr 7 at about $31.51 ($538K). Indirect holdings down 11% to 133,986 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 15, 2026 |
| Apr 2–7, 2026 | Purchase (code P) | Israel A. Englander (10% owner) bought 4,215 shares indirectly between Apr 2 and Apr 7 at about $33.54 ($141K), reported as a purchase (code P). Indirect holdings up 3% to 133,986 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 15, 2026 |
| Mar 31–Apr 1, 2026 | Sale | Israel A. Englander (10% owner) sold 2,741 shares indirectly between Mar 31 and Apr 1 at about $28.07 ($77K). Indirect holdings down 2% to 147,731 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 15, 2026 |
| Mar 31–Apr 1, 2026 | Purchase (code P) | Israel A. Englander (10% owner) bought 12,180 shares indirectly between Mar 31 and Apr 1 at about $31.37 ($382K), reported as a purchase (code P). Indirect holdings up 9% to 147,731 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 15, 2026 |
| Mar 26–30, 2026 | Sale | Israel A. Englander (10% owner) sold 3,250 shares indirectly between Mar 26 and Mar 30 at about $27.51 ($89K). Indirect holdings down 2% to 145,678 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 15, 2026 |
| Mar 26–30, 2026 | Purchase (code P) | Israel A. Englander (10% owner) bought 30,585 shares indirectly between Mar 26 and Mar 30 at about $26.75 ($818K), reported as a purchase (code P). Indirect holdings up 27% to 145,678 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 3 other reporting owners. | SEC filing Filed May 15, 2026 |
| Dec 9, 2025 | Sale | Cambrian BioPharma Inc (10% owner) sold 6,612 shares at about $8.25 ($55K). Holdings down 4% to 155,142 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 10, 2025 |
| Dec 8–9, 2025 | Sale | James Peyer (CEO and 10% owner) sold 6,612 shares indirectly between Dec 8, 2025 and Dec 9, 2025 at about $8.25 ($55K). Indirect holdings down 4% to 155,142 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 10, 2025 |
| Dec 4–5, 2025 | Sale | Cambrian BioPharma Inc (10% owner) sold 21,295 shares between Dec 4, 2025 and Dec 5, 2025 at about $10.93 ($233K). Holdings down 12% to 161,359 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 8, 2025 |
| Dec 4–5, 2025 | Sale | James Peyer (CEO and 10% owner) sold 21,295 shares indirectly between Dec 4, 2025 and Dec 5, 2025 at about $10.93 ($233K). Indirect holdings down 12% to 161,359 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 8, 2025 |
17 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$1.2M in purchases since Jun 22, 2026 · Purchases traded Jun 22, 2026 to Jul 1, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Anand Kiran Parikh (CEO) | $55K | Jun 22, 2026 | SEC filing |
| Brian C. Stephenson (CFO) | $406K | Jun 23, 2026 | SEC filing |
| Brian C. Stephenson (CFO) | $401K | Jun 26, 2026 | SEC filing |
| Brian C. Stephenson (CFO) | $326K | Jul 1, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 8:14 AM ET 8-K | Earnings released (Item 2.02) | SEC filing | |
| Oct 27, 2026, 7:33 AM ET 8-K | Executive or director change (Item 5.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow FTH in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.